Skip to content
Industry
This is research, not advice. We’re not SEBI-registered.

Jenburkt Pharmaceuticals share price

524731Other pharmaStandalonePrices to 24 Jun 2026Results to Mar 2026

Price, 200-day average and NIFTY 500

The price is 2.2% above its 200-day average and 60 points ahead of the NIFTY 500 over 5 years

24 Jun 2026₹1,128.10Over 5 years: Jenburkt Pharmaceuticals +131.2%, NIFTY 500 +70.8%
₹500₹1,250Jun 22Jun 24Jun 26

Price growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y−13.7%3Y+16.3%/yr5Y+18.2%/yr10Y+11.4%/yr

EPS and P/E

EPS ₹78.69, up 8% in a year; P/E 14.3

24 Jun 2026₹78.69 EPS
Jun 21
Sep 21
Dec 21
Mar 22
Jun 22
Sep 22
Dec 22
Mar 23
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
₹0₹100

EPS growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+8.3%3Y+12.2%/yr5Y+16.9%/yr10Y+13.7%/yr

Revenue and margins

Revenue up on a year for 9 quarters in a row; operating margin 31.1%, the highest on this chart

Mar 2026 quarter₹45 crore+9.8% on ₹41 crore a year earlier · NPM 24.4%
Mar 23
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
0₹60

Revenue: 1Y change, then growth a year; margins are averages

Revenue growth1Y+11.8%3Y+7.2%/yr to Mar5Y+9.2%/yr to Mar10Y+6.0%/yr to Mar
OPM average3Y25.0%5Y24.0% to Mar
NPM average3Y20.0%5Y19.3% to Mar

Return on capital

ROCE was 27.0% for the year to Mar 2026, up from 23.5% in the year to Mar 2021

Year to Mar 202627.0% ROCE
15%25%Mar 22Mar 24Mar 26

ROCE average

1Y3Y5Y10Y1Y27.0% to Mar3Y26.8% to Mar5Y26.6% to Mar10Y30.0% to Mar

Profit and cash

Cash from operations was 64% of profit over five years, 77% in the year to Mar 2026

Yearly profit, cash from operations and free cash flow, ₹ crore

FY26₹27 crore operating cashProfit ₹35 crore · Free cash ₹13 crore
FY22
FY23
FY24
FY25
FY26
0₹40

Profit growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+6.1%3Y+11.9%/yr to Mar5Y+16.9%/yr to Mar10Y+12.3%/yr to Mar

Reinvestment

Capex was ₹14 crore in the year to Mar 2026, 4.6 times depreciation

FY26₹14 crore capexWork in progress ₹46 crore
FY22
FY23
FY24
FY25
FY26
0₹60

Capex growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y−30.4% to Mar3Y+86.9%/yr to Mar5Y+64.2%/yr to Mar10Y+18.4%/yr to Mar

BorrowingsInsufficient history, from Mar 2023Insufficient history, from Mar 2023

Debt ÷ equity 0.01 at 31 Mar 2026

Mar 2026 balance sheet0.01 debt ÷ equityNet cash ₹51 crore
Mar 22
Jun 22
Sep 22
Dec 22
Mar 23
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
0

Safety

Now3Y ago
Debt ÷ equity0.013Y ago0.02
Int. covern/a3Y agon/a

Operating health

Working capital rose from 17 to 41 days in 5 years

Year to Mar 202641 days working capital
50150Mar 22Mar 24Mar 26
Working cap.411Y+103Y+105Y+24
Debtor531Y+33Y+85Y+6
Inventory1541Y+453Y+625Y+62

OwnershipInsufficient history, from Jun 2023Insufficient history, from Jun 2023

FIIs own 0.00%, up 0.00 points in a year. Promoters hold 46.64%

Share of the company held, %, by quarter end

Mar 2026 quarter0.00% FIIs
0%40%Mar 24Mar 25Mar 26

Change in holding, in points

FIIs1Y0.003YToo short
Promoters1Y−0.043YToo short

Jenburkt Pharmaceuticals Ltd · BSE: 524731 · Pharma - Others · prices and results as of 24 June 2026, updated weekly

Jenburkt Pharmaceuticals share price: ₹1,128.10 at the BSE close on 24 June 2026, the latest close in our records; down 13.7% in the year to that date. Jenburkt Pharmaceuticals (BSE: 524731) is worth ₹498 crore, trades at a P/E of 14.3 and has closed between ₹1,000.30 and ₹1,377.75 over the past 52 weeks. Latest change: best operating margin in 13 quarters.

Growing steadilyBusiness trend from fewer quarters than usual
₹1,128.10Price −13.7% in a year
14.3×P/E higher than 59% of the last 10 years
₹45.0 CrRevenue (Mar 2026) +9.8% on a year ago
₹11.0 CrProfit (Mar 2026) +22.2% on a year ago
31.1%Operating margin +4.3 points on a year ago
27.0%ROCE year to Mar 2026
21.5%ROIC against a 12.0% cost of capital: +9.5 points

Jenburkt Pharmaceuticals Ltd's earnings have grown faster than its share price. Earnings per share grew +8.3% in a year while the price moved −13.7%.

Biggest thing to watch: the price has already been rising for 3 weeks, so timing is the risk more than the business.

The price has been rising for 3 weeks, and the P/E is higher than 59% of its own last 10 years. Over the last four quarters, results have been improving, with profit +22.2% on a year earlier, and 68% of the last 3 years' profit came in as cash. What will decide it: the next one or two quarters of results.

Figures we could not check: Some figures on this page come from a second data source that we could not check against the main one, because the two do not cover enough of the same periods. They are shown because they are the only figures there are, and every section that uses one is marked unverified.

What is the Jenburkt Pharmaceuticals share price?

Jenburkt Pharmaceuticals Ltd's share price was ₹1,128.10 at the close on 24 June 2026. It has been rising for 3 weeks. That is 2.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,000 and ₹1,378, and at that close it sat 34% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Jenburkt Pharmaceuticals Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 13 weeks in a row.

Week by week since 2016: did it beat the NIFTY 500 over the past 13 weeks?

Ahead in 246 of 519 weeks

Week by week since 2016: did it beat the NIFTY 500 over the past 13 weeks?
Week13-week return vs NIFTY 500
13 May 2016no NIFTY 500 reading
20 May 2016no NIFTY 500 reading
27 May 2016no NIFTY 500 reading
3 Jun 2016no NIFTY 500 reading
10 Jun 2016no NIFTY 500 reading
17 Jun 2016no NIFTY 500 reading
24 Jun 2016no NIFTY 500 reading
1 Jul 2016no NIFTY 500 reading
8 Jul 2016no NIFTY 500 reading
15 Jul 2016no NIFTY 500 reading
22 Jul 2016no NIFTY 500 reading
29 Jul 2016no NIFTY 500 reading
5 Aug 2016no NIFTY 500 reading
12 Aug 2016−36.1%
19 Aug 2016−32.7%
26 Aug 2016−27.4%
2 Sep 2016−18.0%
9 Sep 2016−19.8%
16 Sep 2016−19.8%
23 Sep 2016−17.5%
30 Sep 2016−9.9%
7 Oct 2016−13.1%
14 Oct 2016−6.0%
21 Oct 2016−2.7%
30 Oct 2016+35.6%
4 Nov 2016+60.3%
11 Nov 2016+44.5%
18 Nov 2016+40.9%
25 Nov 2016+47.6%
2 Dec 2016+54.0%
9 Dec 2016+54.1%
16 Dec 2016+43.6%
23 Dec 2016+45.4%
30 Dec 2016+41.5%
6 Jan 2017+45.6%
13 Jan 2017+37.0%
20 Jan 2017+33.8%
27 Jan 2017−3.9%
3 Feb 2017−20.4%
10 Feb 2017−11.2%
17 Feb 2017−16.3%
23 Feb 2017−22.2%
3 Mar 2017−25.2%
10 Mar 2017−23.6%
17 Mar 2017−23.5%
24 Mar 2017−22.5%
31 Mar 2017−17.5%
7 Apr 2017−19.5%
13 Apr 2017−11.7%
21 Apr 2017−14.4%
28 Apr 2017−16.2%
5 May 2017−13.7%
12 May 2017−14.9%
19 May 2017−12.9%
26 May 2017−17.8%
2 Jun 2017−2.6%
9 Jun 2017+6.0%
16 Jun 2017+14.8%
23 Jun 2017+7.7%
30 Jun 2017+2.0%
7 Jul 2017+3.6%
14 Jul 2017−1.8%
21 Jul 2017−0.7%
28 Jul 2017+3.5%
4 Aug 2017+2.4%
11 Aug 2017+2.7%
18 Aug 2017−2.6%
24 Aug 2017−2.1%
1 Sep 2017−15.9%
8 Sep 2017−11.9%
15 Sep 2017−23.1%
22 Sep 2017−16.8%
29 Sep 2017−13.5%
6 Oct 2017−14.2%
13 Oct 2017−13.1%
19 Oct 2017−10.9%
27 Oct 2017−11.4%
3 Nov 2017−5.3%
10 Nov 2017−7.4%
17 Nov 2017−3.7%
24 Nov 2017+2.3%
1 Dec 2017+7.1%
8 Dec 2017+8.3%
15 Dec 2017+19.1%
22 Dec 2017+23.4%
29 Dec 2017+25.5%
5 Jan 2018+25.6%
12 Jan 2018+23.4%
19 Jan 2018+13.4%
25 Jan 2018+17.4%
2 Feb 2018+12.7%
9 Feb 2018+28.6%
16 Feb 2018+21.8%
23 Feb 2018+22.1%
1 Mar 2018+40.7%
9 Mar 2018+19.9%
16 Mar 2018+24.5%
23 Mar 2018+7.0%
28 Mar 2018+4.5%
6 Apr 2018+18.2%
13 Apr 2018+23.0%
20 Apr 2018+31.5%
27 Apr 2018+29.8%
4 May 2018+22.2%
11 May 2018+10.8%
18 May 2018+14.8%
25 May 2018+24.0%
1 Jun 2018+5.5%
8 Jun 2018+13.7%
15 Jun 2018+5.6%
22 Jun 2018+13.0%
29 Jun 2018+11.4%
6 Jul 2018−1.8%
13 Jul 2018−2.8%
20 Jul 2018−0.7%
27 Jul 2018+1.4%
3 Aug 2018+6.5%
10 Aug 2018+6.1%
17 Aug 2018+8.1%
24 Aug 2018−0.4%
31 Aug 2018−5.2%
7 Sep 2018−6.3%
14 Sep 2018+10.4%
21 Sep 2018+8.9%
28 Sep 2018+6.4%
5 Oct 2018+6.4%
12 Oct 2018−1.2%
19 Oct 2018−4.9%
26 Oct 2018−3.3%
2 Nov 2018−5.2%
9 Nov 2018−4.5%
16 Nov 2018−6.2%
22 Nov 2018−7.1%
30 Nov 2018−5.7%
7 Dec 2018−13.0%
14 Dec 2018−21.9%
21 Dec 2018−25.1%
28 Dec 2018−23.4%
4 Jan 2019−23.3%
11 Jan 2019−23.5%
18 Jan 2019−25.5%
25 Jan 2019−26.6%
1 Feb 2019−24.5%
8 Feb 2019−26.1%
15 Feb 2019−22.1%
22 Feb 2019−25.9%
1 Mar 2019−20.0%
8 Mar 2019−15.3%
15 Mar 2019−20.7%
22 Mar 2019−13.5%
29 Mar 2019−16.9%
5 Apr 2019−16.6%
12 Apr 2019−11.2%
18 Apr 2019−8.6%
26 Apr 2019−11.3%
3 May 2019−9.8%
10 May 2019−4.2%
17 May 2019−8.6%
24 May 2019−4.5%
31 May 2019−2.2%
7 Jun 2019−2.0%
14 Jun 2019+2.5%
21 Jun 2019+1.7%
28 Jun 2019+3.1%
5 Jul 2019+3.3%
12 Jul 2019+6.5%
19 Jul 2019+9.8%
26 Jul 2019+12.2%
2 Aug 2019−5.0%
9 Aug 2019−8.9%
16 Aug 2019−1.9%
23 Aug 2019−2.9%
30 Aug 2019−10.2%
6 Sep 2019−11.0%
13 Sep 2019−9.0%
20 Sep 2019−12.8%
27 Sep 2019−12.7%
4 Oct 2019−13.8%
11 Oct 2019−19.6%
18 Oct 2019−22.3%
27 Oct 2019−18.7%
1 Nov 2019−6.4%
8 Nov 2019−3.9%
15 Nov 2019−13.8%
22 Nov 2019−11.5%
29 Nov 2019−13.4%
6 Dec 2019−12.9%
13 Dec 2019−17.9%
20 Dec 2019−16.6%
27 Dec 2019−13.0%
3 Jan 2020−16.5%
10 Jan 2020+5.6%
17 Jan 2020+1.1%
24 Jan 2020−5.5%
1 Feb 2020−6.1%
7 Feb 2020−6.7%
14 Feb 2020−10.0%
20 Feb 2020−13.3%
28 Feb 2020+3.6%
6 Mar 2020+0.2%
13 Mar 2020+2.9%
20 Mar 2020+7.6%
27 Mar 2020+8.7%
3 Apr 2020+8.7%
9 Apr 2020−5.8%
17 Apr 2020+0.0%
24 Apr 2020−2.7%
30 Apr 2020+1.4%
8 May 2020+3.6%
15 May 2020+11.1%
22 May 2020+10.1%
29 May 2020−0.9%
5 Jun 2020+9.0%
12 Jun 2020+7.0%
19 Jun 2020+4.2%
26 Jun 2020−3.7%
3 Jul 2020−7.8%
10 Jul 2020−0.4%
17 Jul 2020−3.0%
24 Jul 2020+0.9%
31 Jul 2020+18.0%
7 Aug 2020+15.1%
14 Aug 2020+5.1%
21 Aug 2020+7.4%
28 Aug 2020−3.6%
4 Sep 2020−17.8%
11 Sep 2020−19.1%
18 Sep 2020−6.5%
25 Sep 2020−7.2%
1 Oct 2020−4.0%
9 Oct 2020−12.5%
16 Oct 2020−15.5%
23 Oct 2020−13.7%
30 Oct 2020−23.1%
6 Nov 2020−16.9%
14 Nov 2020−17.5%
20 Nov 2020−18.4%
27 Nov 2020−10.4%
4 Dec 2020−5.5%
11 Dec 2020+4.6%
18 Dec 2020−12.7%
24 Dec 2020−12.1%
1 Jan 2021−13.2%
8 Jan 2021−6.1%
15 Jan 2021−8.8%
22 Jan 2021−8.7%
29 Jan 2021−9.8%
5 Feb 2021−27.7%
12 Feb 2021−18.5%
19 Feb 2021−15.4%
26 Feb 2021−15.3%
5 Mar 2021−16.9%
12 Mar 2021−21.9%
19 Mar 2021−17.9%
26 Mar 2021−14.4%
1 Apr 2021−12.6%
9 Apr 2021−11.8%
16 Apr 2021−1.0%
23 Apr 2021+6.4%
30 Apr 2021+0.1%
7 May 2021+9.9%
14 May 2021+13.6%
21 May 2021+14.6%
28 May 2021+27.6%
4 Jun 2021+23.9%
11 Jun 2021+17.1%
18 Jun 2021+13.5%
25 Jun 2021+11.7%
2 Jul 2021+10.2%
9 Jul 2021+10.6%
16 Jul 2021+7.3%
23 Jul 2021+1.1%
30 Jul 2021+3.0%
6 Aug 2021−1.1%
13 Aug 2021−1.4%
20 Aug 2021−5.0%
27 Aug 2021−13.4%
3 Sep 2021−14.3%
9 Sep 2021−9.4%
17 Sep 2021−11.6%
24 Sep 2021−12.8%
1 Oct 2021−9.7%
8 Oct 2021−10.6%
14 Oct 2021−17.8%
22 Oct 2021−18.8%
29 Oct 2021+3.2%
4 Nov 2021+2.2%
12 Nov 2021−4.1%
18 Nov 2021+0.1%
26 Nov 2021+1.8%
3 Dec 2021+8.1%
10 Dec 2021+8.6%
17 Dec 2021+11.2%
24 Dec 2021+14.0%
31 Dec 2021+11.0%
7 Jan 2022+17.0%
14 Jan 2022+25.5%
21 Jan 2022+36.3%
28 Jan 2022+11.4%
4 Feb 2022+5.6%
11 Feb 2022+3.9%
18 Feb 2022+0.3%
25 Feb 2022−0.2%
4 Mar 2022+1.7%
11 Mar 2022+5.5%
17 Mar 2022+1.3%
25 Mar 2022+0.0%
1 Apr 2022+7.4%
8 Apr 2022+5.5%
13 Apr 2022+2.0%
22 Apr 2022−3.2%
29 Apr 2022−4.7%
6 May 2022+2.7%
13 May 2022+5.6%
20 May 2022+12.2%
27 May 2022+7.9%
3 Jun 2022+6.5%
10 Jun 2022+4.4%
17 Jun 2022+2.1%
24 Jun 2022−0.6%
1 Jul 2022−4.2%
8 Jul 2022−4.8%
15 Jul 2022−4.0%
22 Jul 2022−13.3%
29 Jul 2022−10.2%
5 Aug 2022−8.5%
12 Aug 2022−8.0%
19 Aug 2022−3.5%
26 Aug 2022+2.2%
2 Sep 2022−0.9%
9 Sep 2022−3.7%
16 Sep 2022+7.0%
23 Sep 2022+3.5%
30 Sep 2022+0.9%
7 Oct 2022−3.2%
14 Oct 2022−0.3%
21 Oct 2022+3.9%
28 Oct 2022+4.0%
4 Nov 2022+3.0%
11 Nov 2022+4.2%
18 Nov 2022−3.1%
25 Nov 2022−6.2%
2 Dec 2022+0.8%
9 Dec 2022+4.5%
16 Dec 2022+5.7%
23 Dec 2022+12.3%
30 Dec 2022+15.3%
6 Jan 2023+16.8%
13 Jan 2023+12.5%
20 Jan 2023+14.2%
27 Jan 2023+14.6%
3 Feb 2023+14.4%
10 Feb 2023+10.4%
17 Feb 2023+12.1%
24 Feb 2023+14.3%
3 Mar 2023+10.1%
10 Mar 2023+9.3%
17 Mar 2023+12.4%
24 Mar 2023+13.1%
31 Mar 2023+8.2%
6 Apr 2023+7.2%
13 Apr 2023+8.4%
21 Apr 2023+11.5%
28 Apr 2023+7.7%
5 May 2023+9.0%
12 May 2023+14.2%
19 May 2023+12.4%
26 May 2023+14.5%
2 Jun 2023+12.5%
9 Jun 2023−6.4%
16 Jun 2023−7.4%
23 Jun 2023−7.1%
30 Jun 2023−4.4%
7 Jul 2023−4.9%
14 Jul 2023−1.6%
21 Jul 2023−7.8%
28 Jul 2023−6.5%
4 Aug 2023−5.1%
11 Aug 2023−7.4%
18 Aug 2023−11.0%
25 Aug 2023−15.1%
1 Sep 2023−16.4%
8 Sep 2023−4.4%
15 Sep 2023−11.9%
22 Sep 2023−12.2%
29 Sep 2023−8.3%
6 Oct 2023−9.7%
13 Oct 2023−13.0%
20 Oct 2023−16.0%
27 Oct 2023−13.4%
3 Nov 2023−14.3%
12 Nov 2023−11.2%
17 Nov 2023−9.6%
24 Nov 2023−10.5%
1 Dec 2023−8.2%
8 Dec 2023−10.8%
15 Dec 2023−10.5%
22 Dec 2023−11.2%
29 Dec 2023−15.2%
5 Jan 2024−8.0%
12 Jan 2024+3.5%
20 Jan 2024+18.6%
25 Jan 2024+27.2%
2 Feb 2024+13.6%
9 Feb 2024−0.9%
16 Feb 2024+0.4%
23 Feb 2024−0.1%
2 Mar 2024+2.6%
7 Mar 2024+2.1%
15 Mar 2024−1.3%
22 Mar 2024−2.0%
28 Mar 2024−2.9%
5 Apr 2024−2.4%
12 Apr 2024−12.1%
19 Apr 2024−16.5%
26 Apr 2024−24.8%
3 May 2024−6.2%
10 May 2024−1.2%
18 May 2024−4.6%
24 May 2024−3.5%
31 May 2024+2.2%
7 Jun 2024+7.1%
14 Jun 2024+8.4%
21 Jun 2024+12.3%
28 Jun 2024+15.2%
5 Jul 2024+6.8%
12 Jul 2024+6.2%
19 Jul 2024+5.4%
26 Jul 2024+10.0%
2 Aug 2024−2.7%
9 Aug 2024+1.3%
16 Aug 2024+6.3%
23 Aug 2024+29.5%
30 Aug 2024+20.1%
6 Sep 2024+26.3%
13 Sep 2024+25.1%
20 Sep 2024+20.7%
27 Sep 2024+15.9%
4 Oct 2024+10.7%
11 Oct 2024+18.3%
18 Oct 2024+19.6%
25 Oct 2024+7.5%
1 Nov 2024+10.3%
8 Nov 2024+39.6%
14 Nov 2024+36.8%
22 Nov 2024+11.3%
29 Nov 2024+14.7%
6 Dec 2024+8.7%
13 Dec 2024+19.5%
20 Dec 2024+18.7%
27 Dec 2024+17.7%
3 Jan 2025+32.7%
10 Jan 2025+27.8%
17 Jan 2025+24.7%
24 Jan 2025+34.2%
1 Feb 2025+18.7%
7 Feb 2025−2.8%
14 Feb 2025−8.0%
21 Feb 2025−6.7%
28 Feb 2025−11.1%
7 Mar 2025−8.4%
13 Mar 2025−13.4%
21 Mar 2025−15.2%
28 Mar 2025−9.8%
4 Apr 2025−10.1%
11 Apr 2025−13.6%
17 Apr 2025−9.5%
25 Apr 2025−15.5%
2 May 2025−10.0%
9 May 2025−13.8%
16 May 2025−5.3%
23 May 2025+6.8%
30 May 2025+6.2%
6 Jun 2025+19.6%
13 Jun 2025+24.2%
20 Jun 2025+22.3%
27 Jun 2025+18.5%
4 Jul 2025+18.5%
11 Jul 2025+16.4%
18 Jul 2025+8.2%
25 Jul 2025+19.4%
1 Aug 2025+21.3%
8 Aug 2025+15.6%
14 Aug 2025+8.5%
22 Aug 2025−4.1%
29 Aug 2025−1.9%
5 Sep 2025−9.4%
12 Sep 2025−18.0%
19 Sep 2025−16.8%
26 Sep 2025−13.8%
3 Oct 2025−19.7%
10 Oct 2025−19.5%
17 Oct 2025−24.1%
24 Oct 2025−22.0%
31 Oct 2025−5.0%
7 Nov 2025−5.2%
14 Nov 2025+0.0%
21 Nov 2025+5.9%
28 Nov 2025+0.1%
5 Dec 2025−10.4%
12 Dec 2025−3.1%
19 Dec 2025−2.4%
26 Dec 2025−4.9%
2 Jan 2026+0.9%
9 Jan 2026+0.6%
16 Jan 2026+11.1%
23 Jan 2026+0.0%
1 Feb 2026−14.9%
6 Feb 2026−10.3%
13 Feb 2026−11.8%
20 Feb 2026−15.8%
27 Feb 2026−10.8%
6 Mar 2026−2.8%
13 Mar 2026+2.8%
20 Mar 2026+2.4%
27 Mar 2026+5.7%
2 Apr 2026+2.4%
10 Apr 2026+0.8%
17 Apr 2026−5.1%
24 Apr 2026+2.5%
30 Apr 2026+1.2%
8 May 2026+10.7%
15 May 2026+16.9%
22 May 2026+15.7%
29 May 2026+16.9%
5 Jun 2026+13.8%
9 Jun 2026+9.2%
10 Jun 2026+11.0%
12 Jun 2026+10.0%
17 Jun 2026+2.9%
19 Jun 2026+4.9%
24 Jun 2026+8.9%
Each bar is one week, from 2016 to now (519 weeks with a reading). Green means the stock's return over the previous 13 weeks beat the NIFTY 500; red means it trailed. The colour is strongest at a gap of 25 percentage points or more. A gap means there is no reading for that week.

Over the last 10 years the share price moved +145% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

What changed at Jenburkt Pharmaceuticals this quarter?

Three changes stood out: best operating margin in 13 quarters, revenue up on a year earlier for 9 quarters in a row (every quarter we can compare) and promoters cut their stake for 6 quarters in a row.

  1. Best operating margin in 13 quarters

    Operating margin was 32% in the March 2026 quarter, against 26% a year earlier.

  2. Revenue up on a year earlier for 9 quarters in a row (every quarter we can compare)

    In the March 2026 quarter revenue was ₹45 crore, +9.8% on a year earlier.

  3. Promoters cut their stake for 6 quarters in a row

    From 46.7% to 46.6% of the company by the March 2026 quarter.

What are Jenburkt Pharmaceuticals' latest quarterly results?

For January to March 2026 (the quarter ended 31 March 2026), Jenburkt Pharmaceuticals reported revenue of ₹45.0 crore, up 9.8% from ₹41.0 crore a year earlier, and a profit of ₹11.0 crore, up 22.2% from ₹9.00 crore.

Jenburkt Pharmaceuticals results: January to March 2026 against a year earlier

Jenburkt Pharmaceuticals results: January to March 2026 against a year earlier
MeasureJanuary to March 2026January to March 2025Change
Revenue₹45.0 crore₹41.0 crore+9.8%
Profit₹11.0 crore₹9.00 crore+22.2%
Earnings per share₹24.58₹19.35+27.0%
Operating margin31.1%26.8%+4.3 points

The next results, for April to June 2026, are due by 14 August 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 31 March 2026). Revenue and profit in ₹ crore.

What is the Jenburkt Pharmaceuticals share price history?

Jenburkt Pharmaceuticals closed at ₹1,128.10 on 24 June 2026, down 13.7% from ₹1,307.35 a year earlier (27 June 2025) and up 131.2% over five years. Its highest weekly close since May 2016 was ₹1,377.75 on 4 July 2025.

Jenburkt Pharmaceuticals share price: then and now

Jenburkt Pharmaceuticals share price: then and now
WhenCloseChange to 24 Jun 2026
1 week ago · 17 Jun 2026₹1,148.90−1.8%
1 month ago · 22 May 2026₹1,154.70−2.3%
6 months ago · 26 Dec 2025₹1,074.70+5.0%
1 year ago · 27 Jun 2025₹1,307.35−13.7%
3 years ago · 23 Jun 2023₹717.35+57.3%
5 years ago · 25 Jun 2021₹488.00+131.2%
10 years ago · 24 Jun 2016₹383.90+193.9%
Earliest weekly close in our records · 13 May 2016₹460.50+145.0%
Highest weekly close since May 2016, also the 52-week high · 4 Jul 2025₹1,377.75−18.1%
Lowest weekly close since May 2016 · 3 Apr 2020₹298.10+278.4%
52-week low (weekly close) · 6 Mar 2026₹1,000.30+12.8%

Weekly closing prices. Each change is the move from that price to the 24 Jun 2026 close. A day's intraday high or low can go beyond these weekly closes.

532 weekly closes from 13 May 2016 to 24 June 2026.

What is the latest news on Jenburkt Pharmaceuticals?

24 Jun 2026: Jenburkt Pharmaceuticals closed at ₹1,128.10, down 1.8% on the week and down 2.3% on the month. Results for January to March 2026: Revenue up 9.8% and profit up 22.2% on a year earlier.

What dividend does Jenburkt Pharmaceuticals pay?

Yes. Jenburkt Pharmaceuticals Ltd paid out 26% of its profit as dividends in FY26, and it paid a dividend in each of its last 12 reported years. This page shows the payout as a share of profit, not an amount per share (as of 24 June 2026).

What to watch in Jenburkt Pharmaceuticals' next results?

When Jenburkt Pharmaceuticals reports April to June 2026, these are the 4 checks that show whether the story is still on course. First: Revenue against the same quarter a year earlier.

  • Revenue against the same quarter a year earlier. In the Mar 2026 quarter, revenue was +9.8% on a year earlier, and the last four quarters averaged +11.8%.
  • Whether the operating margin stays near 31.1%. It is 4.3 percentage points higher than four quarters earlier.
  • Net profit against the same quarter a year earlier. In the Mar 2026 quarter, profit was +22.2% on a year earlier.
  • Whether cash from operations catches up with profit. Only 68% of the last 3 years' profit came in as cash from operations.

Which stock lists is Jenburkt Pharmaceuticals on?

Jenburkt Pharmaceuticals is not on any of our India lists this week.

Is Jenburkt Pharmaceuticals profitable?

Jenburkt Pharmaceuticals Ltd earned ₹11.0 Cr of net profit in the Mar 2026 quarter, +22.2% on the same quarter a year earlier. Full-year FY26 profit was ₹35.0 Cr. Over 10 years profit has grown 12.3% a year on average. The Mar 2026 quarter's profit is 24.4% of that quarter's revenue. The same quarter a year earlier earned ₹9.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹35.0 Cr (+9.4% on the year before).

Why profit moved: revenue changed +9.8% on a year earlier and the margin moved +4.3 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +5.5% and revenue +11.8%. Profit is growing slower than sales: rising costs are taking part of the growth.

How much revenue does Jenburkt Pharmaceuticals make, and is it growing?

Jenburkt Pharmaceuticals Ltd reported ₹45.0 Cr of revenue in the Mar 2026 quarter, +9.8% on the same quarter a year earlier. That is the 9th quarter in a row with growth on the year before. Over 10 years it has grown 6.0% a year on average. The last full year, FY26, came in at ₹169 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹170 Cr.

FY26 revenue was ₹169 Cr, +11.2% on the year before.

Recent pace: the last four quarters grew +11.8% on average, against 6.0% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +11.8%, against +9.4% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +6.1%, against +18.3% a year (rolling over).

How much of every ₹100 of sales does Jenburkt Pharmaceuticals keep?

Jenburkt Pharmaceuticals Ltd's operating margin was 31.1% in the Mar 2026 quarter, 4.3 percentage points higher than the same quarter a year ago. Across 12 years it has been between 16.8% and 26.3%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +5.5 percentage points on the year while gross margin changed −0.2 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Is Jenburkt Pharmaceuticals' profit turning into cash?

Over the last 3 years, 68% of Jenburkt Pharmaceuticals Ltd's reported profit came in as cash from its operations, so most of the profit is real cash. In FY26 it brought in ₹27.0 Cr of operating cash against ₹35.0 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After ₹13.0 Cr of estimated spending on assets (worked out from the change in fixed assets plus depreciation; no filed figure), ₹14.0 Cr was left over as free cash.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 68% of profit came in as cash: the cash cycle got 32 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 32 days longer. The next section looks at where the cash is stuck.

Where does Jenburkt Pharmaceuticals' cash go?

Jenburkt Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 115 days in FY26, up from 83 days in FY21. It spent ₹62.0 Cr on assets over the last 3 years. Customers take 53 days to pay, and stock sits for 154 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹169 Cr, each day of that cycle ties up about ₹0.5 Cr, so roughly ₹53.0 Cr is tied up in the business at any time.

FY26: customers took 53 days to pay and stock sat for 154 days, about 5.1 months of sales sitting as stock, for a full cycle of 115 days, longer than FY21's 83.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 154 days. Customers pay about 53 days after that. Suppliers are paid at 91 days. Together that makes the 115-day cycle.

Spending on assets: ₹62.0 Cr over the last 3 years, against ₹8.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹46.0 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

What is Jenburkt Pharmaceuticals' P/E ratio, and how does it compare with its own history?

Jenburkt Pharmaceuticals Ltd's P/E is 14.3×, in the middle of its own history: higher than 59% of past readings. Its usual P/E (the middle reading) is 13.8×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Mar 2026 add up to ₹78.69.

14.3×P/E · higher than 59% of its last 10 years

Why the multiple is where it is: over the past year earnings per share moved +8.3% while the price moved −13.7%. Earnings did better than the price, which pulled the multiple down within its own range.

Where the price move came from: over 5 years the price moved +18.2% a year; about +16.9% a year came from earnings growth and about +1.3 percentage points from the multiple (the market paying more); over 10 years the price moved +11.4% a year; about +13.7% a year came from earnings growth and about −2.3 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple.

What growth does the Jenburkt Pharmaceuticals share price assume?

Worked out from its price on 13 June 2026, Jenburkt Pharmaceuticals Ltd's share price assumed profit growth of about 5.9% a year. Over the past 10 years its profit actually grew 12.3% a year. Today its P/E is 14.3×, higher than 59% of its own last 10 years.

This works the share price backwards. It asks one question: what yearly profit growth does the price already assume? The answer is the growth rate at which eleven years of profit (six years of growth, then five years of slowing) add up to that day's market value, after each year is discounted at 11%.

This is a one-day reading, taken on 13 June 2026. Every other number on this page, the multiple included, uses the latest price as of 24 June 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements.

Is the Jenburkt Pharmaceuticals business getting better or worse?

Jenburkt Pharmaceuticals Ltd's business is growing steadily. Revenue and profit growth have stayed positive throughout, and ROCE is steady at 27.0% (year to Mar 2026). This is based on 9 quarters of 3 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Steady highRevenue growth · latest (Mar 2026) +9.8%, range +2.8% to +16.2%
Steady highProfit growth · latest (Mar 2026) +22.2%, range −14.3% to +40.0%
Steady highROCE · latest (year to Mar 2026) 27.0%, range 26.0% to 27.0%

Why it matters: steady growth with healthy returns is how a business compounds over time.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Compound annual growth rate (%)
Measure1yr3yr5yr10yr
Revenue+11.2%+7.2%+9.2%+6.0%
Profit+9.4%+11.9%+16.9%+12.3%
EPS+8.4%+12.2%+17.0%+13.0%
Share price−13.7%+16.3%+18.2%+11.4%
+9.8%Revenue growth (Mar 2026) · latest quarter against a year ago
+22.2%Profit growth (Mar 2026) · latest quarter against a year ago
6.0%Revenue, 10 years · yearly growth over the long run

How much does Jenburkt Pharmaceuticals earn on its capital?

Jenburkt Pharmaceuticals Ltd earned a ROCE of 27% in FY26. That is up from a low of 24% in FY21. Its return on capital used (ROIC) is 9.5 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 20.7% net margin and 0.75× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 20.7% net margin × 0.75× asset turnover × 1.15× leverage (assets divided by equity) ≈ 17.9% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 21.5% − 12.0% = +9.5 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.

Does Jenburkt Pharmaceuticals have too much debt?

Jenburkt Pharmaceuticals Ltd had ₹2.0 Cr of borrowings against ₹197 Cr of equity in FY26, so its debt is 0.01× its equity. Over 5 years borrowings went from ₹5.0 Cr to ₹2.0 Cr. Over the last 3 of those years it spent ₹62.0 Cr on assets.

Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.

The spending on assets is being paid for from cash, not new debt.

What is the Jenburkt Pharmaceuticals shareholding pattern?

No group of Jenburkt Pharmaceuticals Ltd's owners changed its stake by a full percentage point over the last two years. Domestic institutions moved +0.1 points over the same period, to 0.1%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Promoters: −0.6 points over 8 quarters, to 46.6%; Domestic institutions: +0.1 points over 8 quarters, to 0.1%; Foreign institutions: +0.0 points over 8 quarters, to 0.0%.

How far is Jenburkt Pharmaceuticals from balance-sheet trouble?

For Jenburkt Pharmaceuticals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

How does Jenburkt Pharmaceuticals rank in its industry?

55.3 out of 100, rank 9 of 10 in Pharma - Others, with 47% of the evidence available. It is provisional, so it is ranked below companies with full evidence.

Jenburkt Pharmaceuticals Ltd scores 55.3 out of 100 against the 10 companies it is compared with in Pharma - Others, ranking 9. Some evidence is missing, so the score is pulled toward the middle on purpose.

The three scored parts add up to the total exactly: 20.1 + 21.7 + 13.5 = 55.3 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Which companies is Jenburkt Pharmaceuticals compared with?

Jenburkt Pharmaceuticals ranks 9 of 10 Pharma - Others companies on the 4-Factor Sector Score, with 55.3 out of 100.

  1. 1Shukra Pharmaceuticals LtdSHUKRAPHAR · breaking out · Most evidence points up · 60% evidence70.9out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 29.8/35 · Revenue 100% · Profit 100% · Operating margin change 57 points · 95% evidenceCapital efficiency 19.1/25 · ROCE 37% (year to Mar 2026) · Operating margin 50% · 76% evidenceValuation 9.5/20 · P/E 73.4× · PEG — · 15% evidenceRelative strength 12.5/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 79.5% · 1 year 101.1% · 25% evidence · 8 of 8 weeks aheadExact sum: 29.8 + 19.1 + 9.5 + 12.5 = 70.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  2. 2Syncom Formulations (India) LtdSYNCOMF · leader · Most evidence points up · 83% evidence66.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 20.0/35 · Revenue 0.4% · Profit 50% · Operating margin change 7 points · 100% evidenceCapital efficiency 18.1/25 · ROCE 24.7% (year to Mar 2026) · Operating margin 22.5% · 100% evidenceValuation 10.2/20 · P/E 21.7× · PEG — · 15% evidenceRelative strength 18.0/20 · Strength vs its industry (price vs its 52-week average, weekly) 0.3% · Strength vs NIFTY 500 (same reading) 27% · 1 year 38.1% · 100% evidence · 12 of 12 weeks aheadExact sum: 20 + 18.1 + 10.2 + 18 = 66.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  3. 3JOJO Ltdleader · Most evidence points up · 60% evidence65.6out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 38.0/43.75 · Revenue 100% · Profit 100% · Operating margin change 109.9 points · 95% evidenceCapital efficiency 16.5/31.25 · ROCE 16.8% (year to Mar 2026) · Operating margin 20.8% · 95% evidenceValuation 11.1/25 · P/E 169.2× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 38 + 16.5 + 11.1 = 65.6 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone.
  4. 4Sun Pharma Advanced Research Company LtdSPARC · turning · Evidence leans up · 81% evidence60.5out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 18.0/35 · Revenue 100% · Profit 100% · Operating margin change 684 points · 74% evidenceCapital efficiency 16.3/25 · ROCE 164% (year to Mar 2026) · Operating margin -153.3% · 100% evidenceValuation 15.0/20 · P/E 3.8× · PEG — · 50% evidenceRelative strength 11.2/20 · Strength vs its industry (price vs its 52-week average, weekly) -9.2% · Strength vs NIFTY 500 (same reading) 15.4% · 1 year 39.8% · 100% evidence · 0 of 12 weeks aheadExact sum: 18 + 16.3 + 15 + 11.2 = 60.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  5. 5TTK Healthcare LtdTTKHLTCARE · quiet · Evidence leans down · 75% evidence48.8out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 19.3/35 · Revenue 11.3% · Profit 100% · Operating margin change -1 points · 100% evidenceCapital efficiency 6.8/25 · ROCE 8% (year to Mar 2026) · Operating margin 1.7% · 100% evidenceValuation 14.7/20 · P/E 5.7× · PEG — · 50% evidenceRelative strength 8.0/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) -6.7% · 1 year -1.6% · 25% evidence · 8 of 12 weeks aheadExact sum: 19.3 + 6.8 + 14.7 + 8 = 48.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  6. 6Remus Pharmaceuticals LtdREMUS · losing its lead · Evidence leans down · 66% evidence48.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 19.0/35 · Revenue 53.9% · Profit 83.3% · Operating margin change 3 points · 48% evidenceCapital efficiency 13.9/25 · ROCE 11.5% (year to Mar 2026) · Operating margin 35.5% · 76% evidenceValuation 11.4/20 · P/E 30.6× · PEG — · 50% evidenceRelative strength 4.0/20 · Strength vs its industry (price vs its 52-week average, weekly) -19.4% · Strength vs NIFTY 500 (same reading) 3.1% · 1 year 17.6% · 100% evidence · 10 of 12 weeks aheadExact sum: 19 + 13.9 + 11.4 + 4 = 48.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  7. 7Unichem Laboratories LtdUNICHEMLAB · quiet · Evidence leans down · 67% evidence36.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 11.3/35 · Revenue 6.4% · Profit 100% · Operating margin change 1 points · 71% evidenceCapital efficiency 7.0/25 · ROCE 4.1% (year to Mar 2026) · Operating margin 11.6% · 76% evidenceValuation 10.8/20 · P/E 9.7× · PEG — · 15% evidenceRelative strength 7.3/20 · Strength vs its industry (price vs its 52-week average, weekly) -14.3% · Strength vs NIFTY 500 (same reading) 9.2% · 1 year 0.5% · 100% evidence · 6 of 12 weeks aheadExact sum: 11.3 + 7 + 10.8 + 7.3 = 36.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  8. 8Panacea Biotec LtdPANACEABIO · basing · Most evidence points down · 74% evidence28.8out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 16.1/35 · Revenue 19.5% · Profit 100% · Operating margin change 21 points · 74% evidenceCapital efficiency 1.5/25 · ROCE -2.4% (year to Mar 2026) · Operating margin 8.4% · 100% evidenceValuation 9.2/20 · P/E 112× · PEG — · 15% evidenceRelative strength 2.0/20 · Strength vs its industry (price vs its 52-week average, weekly) -32.6% · Strength vs NIFTY 500 (same reading) -12.5% · 1 year -2.7% · 100% evidence · 0 of 12 weeks aheadExact sum: 16.1 + 1.5 + 9.2 + 2 = 28.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  9. 9Jenburkt Pharmaceuticals Ltd this pageToo little evidence to rank firmly · 47% evidence55.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 20.1/43.75 · Revenue 11.8% · Profit 6.1% · Operating margin change 6 points · 53% evidenceCapital efficiency 21.7/31.25 · ROCE 27.2% (year to Mar 2026) · Operating margin 31.1% · 71% evidenceValuation 13.5/25 · P/E 14.3× · PEG — · 50% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 20.1 + 21.7 + 13.5 = 55.3 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  10. 10Madhuveer Com 18 Network LtdMADHUVEER · Too little evidence to rank firmly · 33% evidence42.2out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 19.9/43.75 · Revenue 68.7% · Profit 12.8% · Operating margin change 18.4 points · 45% evidenceCapital efficiency 11.7/31.25 · ROCE -1.1% (year to Mar 2025) · Operating margin 69.7% · 57% evidenceValuation 10.6/25 · P/E 690.9× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 19.9 + 11.7 + 10.6 = 42.2 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Pharma - Others, all 10 compared on one page.

Which companies are close to Jenburkt Pharmaceuticals in size?

Jenburkt Pharmaceuticals is the 10th largest of 10 Pharma - Others companies on Sector Alpha by market value (at the 20 November 2026 close). Just above it: Syncom Formulations (India), Panacea Biotec, TTK Healthcare, JOJO, Remus Pharmaceuticals and Madhuveer Com 18 Network. It is the smallest.

Pharma - Others companies close in size

  1. Syncom Formulations (India) Ltd ₹2,058 crore
  2. Panacea Biotec Ltd ₹2,058 crore
  3. TTK Healthcare Ltd ₹1,569 crore
  4. JOJO Ltd ₹1,568 crore
  5. Remus Pharmaceuticals Ltd ₹964 crore
  6. Madhuveer Com 18 Network Ltd ₹581 crore
  7. Jenburkt Pharmaceuticals Ltd ₹498 crore

All 10 Pharma - Others companies, largest first

Companies close in size in other industries

  1. Davangere Sugar Company Ltd ₹499 crore · Sugar
  2. RMC Switchgears Ltd ₹499 crore · Capital Goods - Switchgear
  3. Jenburkt Pharmaceuticals Ltd ₹498 crore
  4. Brahmaputra Infrastructure Ltd ₹498 crore · Construction - Civil/Turnkey
  5. SK Minerals & Additives Ltd ₹497 crore · Trading

What else do people ask about Jenburkt Pharmaceuticals?

What were Jenburkt Pharmaceuticals's latest quarterly results?

Jenburkt Pharmaceuticals Ltd reported revenue of ₹45.0 Cr and net profit of ₹11.0 Cr for the Mar 2026 quarter. Revenue rose 9.8% and profit rose 22.2% compared with a year earlier. Earnings per share were ₹24.58.

The operating margin was 31.1%, 4.3 percentage points higher than a year earlier (as of 24 June 2026).

What is Jenburkt Pharmaceuticals's market cap?

Jenburkt Pharmaceuticals Ltd's market capitalisation is ₹498 Cr at a share price of ₹1,128.10. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 24 June 2026).

How is Jenburkt Pharmaceuticals performing?

Jenburkt Pharmaceuticals Ltd's share price has been rising for 3 weeks. In its latest quarter, revenue rose 9.8% and profit rose 22.2% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 13 weeks running (as of 24 June 2026).

Will Jenburkt Pharmaceuticals's share price go up?

This page does not forecast Jenburkt Pharmaceuticals Ltd's share price. What it shows instead: the share price is ₹1,128.10, and it has been rising for 3 weeks. Its P/E of 14.3× is higher than 59% of its own last 10 years (as of 24 June 2026).

Who owns Jenburkt Pharmaceuticals?

Promoters own 46.6% of Jenburkt Pharmaceuticals Ltd, foreign institutions 0.0%, domestic institutions 0.1% and the public 53.2% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 24 June 2026).

Where is Jenburkt Pharmaceuticals in its business cycle?

Jenburkt Pharmaceuticals Ltd's FY26 operating margin was 26.0%, against a 12-year range of 16.8% to 26.3%. The latest quarter was 31.1%, above the top of its own yearly range in the latest quarter, so margins are at a high and the story depends on them staying there.

Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 24 June 2026).

What could break the Jenburkt Pharmaceuticals story?

Biggest thing to watch: the price has already been rising for 3 weeks, so timing is the risk more than the business.

On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 24 June 2026).

Is Jenburkt Pharmaceuticals a stock worth studying right now?

What the numbers show: Jenburkt Pharmaceuticals Ltd's earnings have grown faster than its share price. Earnings per share grew +8.3% in a year while the price moved −13.7%. The main open question: the next one or two quarters of results.

Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 24 June 2026).

Where do these numbers come from?

Sector Alpha, written by code from the published numbers. Data as of 24 June 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.

More lists

Every Sector Alpha list, grouped

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.